Document Detail


Use of Prolonged Bivalirudin Infusions Following Percutaneous Coronary Intervention.
MedLine Citation:
PMID:  21479645     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
INTRODUCTION: Antithrombotic therapy plays an integral role in percutaneous coronary intervention (PCI). Bivalirudin has been evaluated in elective procedures and across the spectrum of acute coronary syndromes and is associated with decreased bleeding events compared to unfractionated heparin (UFH) in combination with glycoprotein IIb/IIIa inhibitors (GPI) when used for the duration of PCI. The use of bivalirudin beyond the end of PCI is not as well established but is being explored as an option for specific patients. DISCUSSION: A small increase in stent thrombosis and ischemic events has been identified in large clinical trials using bivalirudin for acute coronary syndromes (ACS). The reasons for this finding are unclear, but may be related to the short duration of bivalirudin or the timing and dose of antiplatelet therapies in the trials. Two small, single center trials have evaluated bivalirudin continued for 4 h beyond the end of PCI. These trials suggest that prolonged bivalirudin infusions result in less periprocedural myocardial infarction with no increase in bleeding compared to intraprocedural only bivalirudin. However, these studies were not powered to identify a difference in bleeding. Efforts to decrease periprocedural myocardial infarction should include the appropriate use of oral antiplatelet agents. An adequate and appropriately timed loading dose of thienopyridines plays a key role in decreasing complications of PCI. CONCLUSION: The strategy of prolonging the bivalirudin infusion at a reduced infusion rate for 4 h after completion of the PCI procedure was explored and offers promising results.
Authors:
Lynette R Moser; Carrie W Nemerovski; Kelley L Good
Related Documents :
17303305 - Perforation of the left atrium by a chest tube in a patient with cardiomegaly: manageme...
15585705 - Mitral valve repair with aortic valve replacement in rheumatic heart disease.
15776845 - View from north america's cardiac surgeons.
16030475 - Impact of papillary muscles approximation on the adequacy of mitral coaptation in funct...
1900225 - Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. r...
20122785 - Transthoracic defibrillation potential gradients in a closed chest porcine model of pro...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-4-9
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  -     ISSN:  1573-7241     ISO Abbreviation:  -     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-4-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Suite 2190, Detroit, MI, 48201, USA, lynette.moser@wayne.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Computed tomography evaluation of the femoral and tibial attachments of the posterior cruciate ligam...
Next Document:  Tobacco use in youth with mental illnesses.